Treatment of Latent Tuberculosis Infection and Its Clinical Efficacy

The role of the treatment for latent tuberculosis infection (LTBI) has been underscored in the intermediate tuberculosis (TB) burden countries like South Korea. LTBI treatment is recommended only for patients at risk for progression to active TB―those with frequent exposure to active TB cases, and those with clinical risk factors (e.g., immunocompromised patients). Recently revised National Institute for Health and Care Excellence (NICE) guideline recommended that close contacts of individuals with active pulmonary or laryngeal TB, aged between 18 and 65 years, should undergo LTBI treatment. Various regimens for LTBI treatment were recommended in NICE, World Health Organization (WHO), and Centers for Disease Control and Prevention guidelines, and superiority of one recommended regimen over another was not yet established. Traditional 6 to 9 months of isoniazid (6H or 9H) regimen has an advantage of the most abundant evidence for clinical efficacy―60%–90% of estimated protective effect. However, 6H or 9H regimen is related with hepatotoxicity and low compliance. Four months of rifampin regimen is characterized by less hepatotoxicity and better compliance than 9H, but has few evidence of clinical efficacy. Three months of isoniazid plus rifampin was proved equivalence with 6H or 9H regimen in terms of efficacy and safety, which was recommended in NICE and WHO guidelines. The clinical efficacy of isoniazid plus rifapentine once-weekly regimen for 3 months was demonstrated recently, which is not yet introduced into South Korea.

keywords: Latent Tuberculosis, Antitubercular Agents, Treatment Outcome, Interferon-Gamma Release Tests, Tuberculin Test, Epidemiology

Reference

Ahmad S. Pathogenesis, immunology, and diagnosis of latent Mycobacterium tuberculosis infection. Clin Dev Immunol 2011;2011:814943.

Ahmad S. New approaches in the diagnosis and treatment of latent tuberculosis infection. Respir Res 2010;11:169.

World Health Organization. Guidelines on the management of latent tuberculosis infection [Internet]. Geneva: World Health Organization; 2015 [cited 2017 Jun 1]. Available from: http://www.who.int/tb/publications/latent-tuberculosisinfection/en/.

Dye C, Glaziou P, Floyd K, Raviglione M. Prospects for tuberculosis elimination. Annu Rev Public Health 2013;34:271-86.

World Health Organization. Global tuberculosis report 2016 [Internet]. Geneva: World Health Organization; 2016 [cited 2017 Jun 1]. Available from: http://www.who.int/tb/publications/global_report/en/.

Kim JH, Yim JJ. Achievements in and challenges of tuberculosis control in South Korea. Emerg Infect Dis 2015;21:1913-20.

Korea Centers for Disease Control and Prevention. Annual report on the notified tuberculosis patients in Korea, 2016. Cheongju: Korea Centers for Disease Control and Prevention; 2017.

Park YK, Park YS, Na KI, Cho EH, Shin SS, Kim HJ. Increased tuberculosis burden due to demographic transition in Korea from 2001 to 2010. Tuberc Respir Dis 2013;74:104-10.

Jeong YJ, Yoon S, Koo HK, Lim HJ, Lee JS, Lee SM, et al. Positive tuberculin skin test or interferon-gamma release assay in patients with radiographic lesion suggesting old healed tuberculosis. J Korean Med Sci 2012;27:761-6.

10.

Small PM, Hopewell PC, Singh SP, Paz A, Parsonnet J, Ruston DC, et al. The epidemiology of tuberculosis in San Francisco: a population-based study using conventional and molecular methods. N Engl J Med 1994;330:1703-9.

11.

Mori T, Leung CC. Tuberculosis in the global aging population. Infect Dis Clin North Am 2010;24:751-68.

12.

Lincoln EM. The effect of antimicrobial therapy on the prognosis of primary tuberculosis in children. Am Rev Tuberc 1954;69:682-9.

13.

Jenkins D, Davidson FF. Isoniazid chemoprophylaxis of tuberculosis. Calif Med 1972;116:1-5.

14.

Runyon EH. Preventive treatment in tuberculosis: a statement by the Committee on Therapy, American Thoracic Society. Am Rev Respir Dis 1965;91:297-8.

15.

Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000;161(4 Pt 2):S221-47.

16.

Public Health England. Tuberculosis in England, 2016 report [Internet]. London: Public Health England; 2016 [cited 2017 Jun 1]. Available from: https://www.gov.uk/government/publications/ tuberculosis-in-england-annual-report.

17.

National Institute for Health and Clinical Excellence (NICE). Tuberculosis (NICE guideline 33) [Internet]. London: NICE; 2016 [cited 2017 Jun 1]. Available from: https://www.nice.org.uk/guidance/ng33.

18.

Salinas JL, Mindra G, Haddad MB, Pratt R, Price SF, Langer AJ. Leveling of tuberculosis incidence: United States, 2013-2015. MMWR Morb Mortal Wkly Rep 2016;65:273-8.

19.

Centers for Disease Control and Prevention. Latent tuberculosis infection: a guide for primary health care providers [Internet]. Atlanta: Centers for Disease Control and Prevention; 2013 [cited 2017 Jun 1]. Available from: https://www.cdc.gov/tb/publications/ltbi/default.htm.

20.

Falk A, Fuchs GF. Prophylaxis with isoniazid in inactive tuberculosis: a Veterans Administration Cooperative Study XII. Chest 1978;73:44-8.

21.

Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 1982;60:555-64.

22.

Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis 1979;119:827-30.

23.

Snider DE Jr, Caras GJ, Koplan JP. Preventive therapy with isoniazid: cost-effectiveness of different durations of therapy. JAMA 1986;255:1579-83.

24.

Bass JB Jr, Farer LS, Hopewell PC, O'Brien R, Jacobs RF, Ruben F, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med 1994;149:1359-74.

25.

Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999;3:847-50.

26.

Public Health Agency of Canada. Canadian tuberculosis standards, 7th edition [Internet]. Ottawa: Public Health Agency of Canada; 2014 [cited 2017 Jun 1]. Available from: http://www.phac-aspc.gc.ca/tbpc-latb/pubs/tb-canada-7/index-eng.php.

27.

Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935-52.

28.

Farer LS. Chemoprophylaxis. Am Rev Respir Dis 1982;125(3 Pt 2):102-7.

29.

Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 1989;140:1189-93.

30.

A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis 1992;145:36-41.

31.

Ziakas PD, Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis 2009;49:1883-9.

32.

Ormerod LP. Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. Arch Dis Child 1998;78:169-71.

33.

Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society. Thorax 1998;53:536-48.

34.

Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 2005;40:670-6.

35.

Stagg HR, Zenner D, Harris RJ, Munoz L, Lipman MC, Abubakar I. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med 2014;161:419-28.

36.

Park SJ, Jo KW, Yoo B, Lee CK, Kim YG, Yang SK, et al. Comparison of LTBI treatment regimens for patients receiving anti-tumour necrosis factor therapy. Int J Tuberc Lung Dis 2015;19:342-8.

37.

Zhang T, Zhang M, Rosenthal IM, Grosset JH, Nuermberger EL. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med 2009;180:1151-7.

38.

Miyazaki E, Chaisson RE, Bishai WR. Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis. Antimicrob Agents Chemother 1999;43:2126-30.

39.

Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011;365:2155-66.

40.

Sterling TR, Moro RN, Borisov AS, Phillips E, Shepherd G, Adkinson NF, et al. Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT Tuberculosis Study. Clin Infect Dis 2015;61:527-35.

바로가기메뉴

Article Contents

Vol.81 No.1

Treatment of Latent Tuberculosis Infection and Its Clinical Efficacy

Abstract

Reference

Tuberculosis & Respiratory Diseases